Effects of a Shuangling Fuzheng anticancer preparation on the proliferation of SGC-7901 cells and immune function in a cyclophosphamide-treated murine model

Table 1 Inhibitory effect of SFAP on proliferation of SGC-7901 cells (mean ± SD)

Group	Dose (mg/L)	A value	Rate Inhibition (%)
Control	0	0.290 ± 0.027	0
SFAP	40	0.248 ± 0.055	14.5
SFAP	80	0.239 ± 0.044	17.6
SFAP	160	0.230 ± 0.034	20.7
SFAP	320	0.220 ± 0.041a	24.1
SFAP	640	0.212 ± 0.009b	26.9
Adriamycin	2	0.125 ± 0.037b	56.9

^aP < 0.05,

^bP < 0.01 vs Control.

Table 2 Influence of SFAP on expression of c-myc protein in SGC-7901 cells (mean ± SD)

Group	Dose (mg/L)	Positive c-myc rate (%)
Control	0	22 ± 6
SFAP	160	11 ± 3b
SFAP	320	9 ± 3b

^bP < 0.01 vs control.

Table 3 Influence of SFAP on T-lymphocyte subsets from peripheral blood in cyclophosphamide-treated mice

Group	Dose (mg/kg)	CD3 (%)	CD4 (%)	CD8 (%)	CD4/CD8
NS control	0	46.2 ± 4.5	28.5 ± 1.4	17.7 ± 2.16	1.6 ± 0.1
CTX control	40	37.5 ± 2.4b	21.5 ± 2.2b	16.3 ± 1.6	1.3 ± 0.1b
SFAP + CTX	50 + 40	38.7 ± 2.2	22.2 ± 2.3	16.7 ± 2.0	1.3 ± 0.2
SFAP + CTX	100 + 40	39.7 ± 3.1	24.2 ± 2.3	16.2 ± 1.5	1.5 ± 0.1c
SFAP + CTX	200 + 40	42.3 ± 2.5d	26.7 ± 2.3d	16.8 ± 1.5	1.6 ± 0.1d

^bP < 0.01 vs NS control;

^cP < 0.05,

^dP < 0.01 vs CTX control group.

Table 4 Influence of SFAP on serum sIL-2R and Ig levels in cyclophosphamide-treated mice (mean ± SD)

Group	Dose(mg/kg)	sIL-2R (pmol/L)	IgA(g/L)	IgG(g/L)	IgM(g/L)
NS control	0	30.4 ± 2.5	2.92 ± 0.84	8.07 ± 0.94	2.31 ± 0.51
CTX control	10	77.8 ± 8.5b	1.77 ± 0.14b	6.35 ± 0.63b	1.68 ± 0.14a
SFAP + CTX	50 + 10	75.9 ± 6.4	2.02 ± 0.31	6.87 ± 0.34	1.82 ± 0.27
SFAP + CTX	100 + 10	59.6 ± 6.1d	2.31 ± 0.48c	7.70 ± 0.37d	2.16 ± 0.33d
SFAP + CTX	200 + 10	52.7 ± 5.7d	3.11 ± 0.72d	7.87 ± 0.59d	2.49 ± 0.46d

^aP< 0.05,

^bP < 0.01 vs NS control ;

^cP< 0.05,

^dP < 0.01 vs CTX control.